Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (USFDA) for Topiramate Extended?Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, a generic version of QUDEXY XR Extended?Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, of Upsher- Smith Laboratories, LLC.
According to IQVIA sales data for the 12 month period ending November 2018, the QUDEXY XR Extended?Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg market achieved annual sales of approximately $84.0 million.
The company’s current portfolio consists of 148 products authorized for distribution in the US marketplace and 54 ANDA’s pending approval with the USFDA. In addition to these internal filings, the company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1511.20 |
Dr. Reddys Lab | 5903.50 |
Cipla | 1346.30 |
Zydus Lifesciences | 917.45 |
Lupin | 1544.40 |
View more.. |